Biosimilars – Forecast – Oncology
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5 billion. Throughout the 2023-2033 forecast period, increasing numbers of branded biologics will lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Oncology
- Oncology MAb Forecasts
- G-CSF Forecasts
- Market Forecast in the Major Pharmaceutical Markets
- Overarching Forecast Assumptions
- Drug-Specific Forecast Assumptions
- Avastin
- Cyramza
- Erbitux
- Herceptin
- Outlook for Herceptin IV
- Outlook for Herceptin SC
- First biosimilars of Herceptin IV in the major pharmaceutical markets
- First biosimilars of Herceptin SC in the major pharmaceutical markets
- Order of entry in the United States (Herceptin IV biosimilars)
- Order of entry in the United States (Herceptin SC biosimilars)
- Order of entry in the EU5 (Herceptin IV biosimilars)
- Order of entry in the EU5 (Herceptin SC biosimilars)
- Order of entry in Japan
- Forecast assumptions
- Market forecast: Herceptin
- Imfinzi
- Kadcyla
- Keytruda
- Opdivo
- Perjeta
- Rituxan / MabThera
- Outlook for Rituxan / MabThera
- First biosimilars of Rituxan in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Forecast assumptions
- Market forecast: Rituxan / MabThera: Oncology
- Market forecast for Rituxan / MabThera: immunology and oncology
- Tecentriq
- Vectibix
- Yervoy
- Neupogen / Gran
- Neulasta / G-Lasta
Related Market Assessment Reports
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
